Product Description
Bristol-Myers Squibb was developing bms-770767, an oral 11beta-HSD! inhibitor, for the treatment of Dyslipidemia (Sourced from: https://clinicaltrials.gov/ct2/show/NCT01058083)
Mechanisms of Action: 11beta-HSD1 Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Bristol-Myers Squibb
Company Location: Eastern America
Company CEO: Giovanni Caforio
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Type 2 Diabetes|Hypercholesterolemia|Dyslipidemia
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT01058083 |
MB117-004 | P2 |
Completed |
Dyslipidemia|Hypercholesterolemia |
2011-03-01 |
2019-03-19 |
Treatments |
|
NCT01046422 |
MB117-003 | P2 |
Completed |
Type 2 Diabetes |
2011-01-01 |
2019-03-19 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|